Antineoplastic Agents. 578. Synthesis of Stilstatins 1 and 2 and Their Water-Soluble Prodrugs
- 19 February 2009
- journal article
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 72 (3), 380-388
- https://doi.org/10.1021/np800608c
Abstract
Efficient syntheses of 3,4-methylenedioxy-4′,5-dimethoxy-2′,3′-dihydroxy-Z-stilbene (stilstatin 1, 2), 3,4,4′-trimethoxy-2′,3′,5-trihydroxy-Z-stilbene (stilstatin 2, 5), and respective phosphate prodrugs have been summarized. Both 2 and 5 were accessed via a convergent step synthesis using phosphonium bromides 6 and 21 in Wittig reactions with 2,3-bis(tert-butyldimethylsilyloxy)-4′-methoxybenzaldehyde 14. Deprotection of silyl ethers 15 and 26 with TBAF furnished 2 and 5, respectively. Phosphorylation of 2 and 5 afforded the phosphoric acid intermediates 17 and 28 for prodrug development. These phosphoric acid precursors were employed in parallel series of reactions to produce a selection of metal cation prodrug candidates. The biological activities of stilstatins 1 (2) and 2 (5) and their respective prodrugs were evaluated against a panel of one murine (P388) and six human cancer cell lines. Compared to combretastatin A-2 (1), stilstatin 1 (2) has an additional vicinal hydroxy group on the B ring, the presence of which was detrimental to the cancer cell line potency; in vivo, however, compound 2 would be predicted to have greater anticancer activity resulting from the o-quinone mechanism of action analogous to that of combretastatin A-1 (4). The substitution of a hydroxy group for a methoxy group on the A ring of combretastatin A-1 (4), resulting in stilstatin 2 (5), gave rise to a modest level of inhibition consistent with that found for 4 against cancer cell lines.Keywords
This publication has 13 references indexed in Scilit:
- Antineoplastic Agents. 552. Oxidation of Combretastatin A-1: Trapping the o-Quinone Intermediate Considered the Metabolic Product of the Corresponding Phosphate ProdrugJournal of Natural Products, 2008
- Oxidative Metabolism of Combretastatin A-1 Produces Quinone Intermediates with the Potential To Bind to Nucleophiles and To Enhance Oxidative Stress via Free RadicalsChemical Research in Toxicology, 2007
- Vascular disrupting agentsBioorganic & Medicinal Chemistry, 2007
- Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor VascularityClinical Cancer Research, 2006
- Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosisInternational Journal of Cancer, 2004
- A Convenient Synthesis of 3,4-Dimethoxy-5-hydroxybenzaldehydeSynthetic Communications, 1998
- First Synthesis of Cotarnone, the Key Intermediate for the Synthesis of CotarnineSynthetic Communications, 1990
- Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4Cellular and Molecular Life Sciences, 1989
- Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2Canadian Journal of Chemistry, 1987
- Isolation, Structure, and Synthesis of Combretastatins A-1 and B-1, Potent New Inhibitors of Microtubule Assembly, Derived from Combretum caffrumJournal of Natural Products, 1987